Hyperlipidaemia and cardiovascular disease: Apolipoprotein measurements and metabolic syndrome as predictors of cardiovascular risk

Current Opinion in Lipidology

Volumn 19, Issue 6, 2008, Pages 624-626

  Deans, Kevin A ^a   Dominiczak, Marek H ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK ASSESSMENT;

AGING; APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS;

EID: 56549089151     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328316c030     Document Type: Editorial

References (9)

1. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372:224-233. A large study in 52 populations worldwide, which shows that ApoB/ApoA-I ratio is a better predictor of cardiovascular risk than the conventional lipid measurements.
2. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358:2026-2033.
3. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS). Circulation 2000; 101:477-484.
4. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94:273-278.
5. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298:776-785.
6. ••] mentioned earlier).
7. ••] mentioned earlier), this review summarizes the previously available evidence for the role of ApoB and ApoA-1 in cardiovascular risk prediction. There are no clear recommendations: acknowledging recent evidence in support of the potential superiority of ApoB and ApoA-1 over the traditional lipid profile in cardiovascular risk prediction, the authors also point out the need for further work on the role of these apolipoproteins as therapeutic targets in dyslipidaemia.
8. •] In the PROSPER population, in those without baseline disease, metabolic syndrome was not associated with increased CVD risk (RR 1.07). It was, however, clearly associated with an increased risk of developing diabetes (RR 4.41). In the BRHS population, metabolic syndrome was modestly associated with incident cardiovascular disease (RR 1.27) and, as in PROSPER, strongly associated with diabetes (7.47). In PROSPER, impaired fasting glucose (IFG) was a better predictor of future diabetes than metabolic syndrome. In BRHS, predictive power of IFG and metabolic syndrome were similar.
9. ••] as mentioned earlier). A good short review of the concept of metabolic syndrome and associated controversies.